2nd Digital Exosome Based Therapeutic Development Summit

The exosome therapeutics field is booming with anticipation as preparations are underway for the first few clinical trials and money pours in through partnerships and pipeline acquisitions. However, more is needed to be done to uncover more scientific knowledge, fine-tune manufacturing methods and prepare trials to meet regulatory expectations.

Considering this, we are delighted to announce the release of the agenda for the 2^nd Digital Exosome Based Therapeutic Development Summit (November 11-12, 2020). Uniting trailblazing teams to advance exosome therapeutics into a clinical and commercial reality. This is your only industry-focused meeting dedicated specifically to evidence-based and regulated exosome-based therapeutic. Bringing together industry leaders and newcomers on the field, it’s two days not to be missed.

Check out the newly released program here.

With 20+ speakers and 2 days of unrivalled in-depth content, join your peers to discuss:

• End-to-end insights on drug development from discovery to scalable manufacturing of GMP-grade exosomes, clinical preparation, commercial strategy and more with Evox Therapeutics, Aruna Bio, Codiak Biosciences and ReNeuron
• Innovations in exosome-based therapeutics, such as their applications in COVID-19 vaccines with Capricor Therapeutics
• Understanding the underlying mechanisms of exosome interactions to inform target identification and development decisions with Scripps Research and University Hospital Essen
• Preparing for clinical trials with key lessons learned from the best in the business such as Aegle Therapeutics
• Over 4+ hours scheduled virtual networking time to connect with the community all from the comfort of your own home or office!

And much more! Download the full event guide.

As competition rises, how are you maximizing the consistency, reliability and efficacy of exosome and EV-based therapeutics? Learn, debate and discuss this November with fellow trailblazers to advance your pipeline development and be among the first to the clinic.